nodes	percent_of_prediction	percent_of_DWPC	metapath
Levorphanol—Cyanosis—Teniposide—lymphatic system cancer	0.036	0.036	CcSEcCtD
Levorphanol—Hypoxia—Fludarabine—lymphatic system cancer	0.0352	0.0352	CcSEcCtD
Levorphanol—Personality disorder—Carmustine—lymphatic system cancer	0.0331	0.0331	CcSEcCtD
Levorphanol—Respiratory failure—Fludarabine—lymphatic system cancer	0.0228	0.0228	CcSEcCtD
Levorphanol—Hypokinesia—Carmustine—lymphatic system cancer	0.0212	0.0212	CcSEcCtD
Levorphanol—Coma—Fludarabine—lymphatic system cancer	0.0204	0.0204	CcSEcCtD
Levorphanol—Thinking abnormal—Carmustine—lymphatic system cancer	0.0156	0.0156	CcSEcCtD
Levorphanol—Injection site reaction—Carmustine—lymphatic system cancer	0.0142	0.0142	CcSEcCtD
Levorphanol—Respiratory failure—Vincristine—lymphatic system cancer	0.0139	0.0139	CcSEcCtD
Levorphanol—Sweating—Teniposide—lymphatic system cancer	0.0136	0.0136	CcSEcCtD
Levorphanol—Dysuria—Fludarabine—lymphatic system cancer	0.0131	0.0131	CcSEcCtD
Levorphanol—Coma—Carmustine—lymphatic system cancer	0.0131	0.0131	CcSEcCtD
Levorphanol—Coma—Vincristine—lymphatic system cancer	0.0125	0.0125	CcSEcCtD
Levorphanol—Abnormal vision—Carmustine—lymphatic system cancer	0.0125	0.0125	CcSEcCtD
Levorphanol—Mental disability—Carmustine—lymphatic system cancer	0.0124	0.0124	CcSEcCtD
Levorphanol—Renal failure—Fludarabine—lymphatic system cancer	0.0123	0.0123	CcSEcCtD
Levorphanol—Flushing—Teniposide—lymphatic system cancer	0.0119	0.0119	CcSEcCtD
Levorphanol—Arrhythmia—Teniposide—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Levorphanol—Amnesia—Carmustine—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Levorphanol—Visual impairment—Fludarabine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Levorphanol—Hypoxia—Methotrexate—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Levorphanol—Diplopia—Carmustine—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Levorphanol—Agitation—Teniposide—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Levorphanol—Arrhythmia—Fludarabine—lymphatic system cancer	0.01	0.01	CcSEcCtD
Levorphanol—Cardiac arrest—Vincristine—lymphatic system cancer	0.00943	0.00943	CcSEcCtD
Levorphanol—Urinary retention—Vincristine—lymphatic system cancer	0.00943	0.00943	CcSEcCtD
Levorphanol—Cyanosis—Methotrexate—lymphatic system cancer	0.00937	0.00937	CcSEcCtD
Levorphanol—Confusional state—Teniposide—lymphatic system cancer	0.00916	0.00916	CcSEcCtD
Levorphanol—Agitation—Fludarabine—lymphatic system cancer	0.00899	0.00899	CcSEcCtD
Levorphanol—Tachycardia—Teniposide—lymphatic system cancer	0.00886	0.00886	CcSEcCtD
Levorphanol—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00878	0.00878	CcSEcCtD
Levorphanol—Pruritus—Mechlorethamine—lymphatic system cancer	0.00871	0.00871	CcSEcCtD
Levorphanol—Hypotension—Teniposide—lymphatic system cancer	0.00848	0.00848	CcSEcCtD
Levorphanol—Convulsion—Fludarabine—lymphatic system cancer	0.00847	0.00847	CcSEcCtD
Levorphanol—Confusional state—Fludarabine—lymphatic system cancer	0.00805	0.00805	CcSEcCtD
Levorphanol—Dysuria—Vincristine—lymphatic system cancer	0.00802	0.00802	CcSEcCtD
Levorphanol—Renal failure—Carmustine—lymphatic system cancer	0.00787	0.00787	CcSEcCtD
Levorphanol—Vomiting—Mechlorethamine—lymphatic system cancer	0.00783	0.00783	CcSEcCtD
Levorphanol—Apnoea—Methotrexate—lymphatic system cancer	0.00782	0.00782	CcSEcCtD
Levorphanol—Rash—Mechlorethamine—lymphatic system cancer	0.00777	0.00777	CcSEcCtD
Levorphanol—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00776	0.00776	CcSEcCtD
Levorphanol—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00771	0.00771	CcSEcCtD
Levorphanol—Flushing—Bleomycin—lymphatic system cancer	0.00764	0.00764	CcSEcCtD
Levorphanol—Feeling abnormal—Teniposide—lymphatic system cancer	0.00748	0.00748	CcSEcCtD
Levorphanol—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00742	0.00742	CcSEcCtD
Levorphanol—Sweating—Vincristine—lymphatic system cancer	0.00733	0.00733	CcSEcCtD
Levorphanol—Renal failure—Mitoxantrone—lymphatic system cancer	0.00732	0.00732	CcSEcCtD
Levorphanol—Nausea—Mechlorethamine—lymphatic system cancer	0.00732	0.00732	CcSEcCtD
Levorphanol—Urticaria—Teniposide—lymphatic system cancer	0.00721	0.00721	CcSEcCtD
Levorphanol—Abdominal pain—Teniposide—lymphatic system cancer	0.00718	0.00718	CcSEcCtD
Levorphanol—Sweating—Mitoxantrone—lymphatic system cancer	0.00714	0.00714	CcSEcCtD
Levorphanol—Dyspepsia—Fludarabine—lymphatic system cancer	0.00702	0.00702	CcSEcCtD
Levorphanol—Visual impairment—Carmustine—lymphatic system cancer	0.00693	0.00693	CcSEcCtD
Levorphanol—Constipation—Fludarabine—lymphatic system cancer	0.00682	0.00682	CcSEcCtD
Levorphanol—Bradycardia—Mitoxantrone—lymphatic system cancer	0.0068	0.0068	CcSEcCtD
Levorphanol—Respiratory failure—Methotrexate—lymphatic system cancer	0.00675	0.00675	CcSEcCtD
Levorphanol—Flushing—Carmustine—lymphatic system cancer	0.00667	0.00667	CcSEcCtD
Levorphanol—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00658	0.00658	CcSEcCtD
Levorphanol—Pruritus—Teniposide—lymphatic system cancer	0.00642	0.00642	CcSEcCtD
Levorphanol—Arrhythmia—Carmustine—lymphatic system cancer	0.00642	0.00642	CcSEcCtD
Levorphanol—Coma—Methotrexate—lymphatic system cancer	0.00606	0.00606	CcSEcCtD
Levorphanol—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00597	0.00597	CcSEcCtD
Levorphanol—Confusional state—Bleomycin—lymphatic system cancer	0.0059	0.0059	CcSEcCtD
Levorphanol—Vomiting—Teniposide—lymphatic system cancer	0.00577	0.00577	CcSEcCtD
Levorphanol—Agitation—Carmustine—lymphatic system cancer	0.00575	0.00575	CcSEcCtD
Levorphanol—Rash—Teniposide—lymphatic system cancer	0.00573	0.00573	CcSEcCtD
Levorphanol—Dermatitis—Teniposide—lymphatic system cancer	0.00572	0.00572	CcSEcCtD
Levorphanol—Pruritus—Fludarabine—lymphatic system cancer	0.00565	0.00565	CcSEcCtD
Levorphanol—Agitation—Vincristine—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Levorphanol—Hypotension—Bleomycin—lymphatic system cancer	0.00547	0.00547	CcSEcCtD
Levorphanol—Convulsion—Carmustine—lymphatic system cancer	0.00542	0.00542	CcSEcCtD
Levorphanol—Nausea—Teniposide—lymphatic system cancer	0.00539	0.00539	CcSEcCtD
Levorphanol—Convulsion—Vincristine—lymphatic system cancer	0.00518	0.00518	CcSEcCtD
Levorphanol—Confusional state—Carmustine—lymphatic system cancer	0.00515	0.00515	CcSEcCtD
Levorphanol—Vomiting—Fludarabine—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Levorphanol—Convulsion—Mitoxantrone—lymphatic system cancer	0.00504	0.00504	CcSEcCtD
Levorphanol—Rash—Fludarabine—lymphatic system cancer	0.00503	0.00503	CcSEcCtD
Levorphanol—Dermatitis—Fludarabine—lymphatic system cancer	0.00503	0.00503	CcSEcCtD
Levorphanol—Tachycardia—Carmustine—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Levorphanol—Lethargy—Methotrexate—lymphatic system cancer	0.00491	0.00491	CcSEcCtD
Levorphanol—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Levorphanol—Confusional state—Mitoxantrone—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Levorphanol—Hypotension—Carmustine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Levorphanol—Nausea—Fludarabine—lymphatic system cancer	0.00474	0.00474	CcSEcCtD
Levorphanol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00471	0.00471	CcSEcCtD
Levorphanol—Shock—Mitoxantrone—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Levorphanol—Urticaria—Bleomycin—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Levorphanol—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Levorphanol—Insomnia—Carmustine—lymphatic system cancer	0.00462	0.00462	CcSEcCtD
Levorphanol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Levorphanol—Mood swings—Methotrexate—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Levorphanol—Hypotension—Vincristine—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Levorphanol—Hypotension—Mitoxantrone—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Levorphanol—Insomnia—Vincristine—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Levorphanol—Constipation—Carmustine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Levorphanol—Feeling abnormal—Carmustine—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Levorphanol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Levorphanol—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Levorphanol—Constipation—Vincristine—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Levorphanol—Pruritus—Bleomycin—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Levorphanol—Constipation—Mitoxantrone—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Levorphanol—Abdominal pain—Carmustine—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Levorphanol—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Levorphanol—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Levorphanol—Dysuria—Methotrexate—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Levorphanol—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Levorphanol—Abdominal pain—Vincristine—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Levorphanol—Urticaria—Mitoxantrone—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Levorphanol—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Levorphanol—Vomiting—Bleomycin—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Levorphanol—Rash—Bleomycin—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Levorphanol—Dermatitis—Bleomycin—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Levorphanol—Renal failure—Methotrexate—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Levorphanol—Sweating—Methotrexate—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Levorphanol—Nausea—Bleomycin—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Levorphanol—Dizziness—Carmustine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Levorphanol—Vomiting—Carmustine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Levorphanol—Dizziness—Vincristine—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Levorphanol—Rash—Carmustine—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Levorphanol—Dermatitis—Carmustine—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Levorphanol—Visual impairment—Methotrexate—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Levorphanol—Vomiting—Vincristine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Levorphanol—Rash—Vincristine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Levorphanol—Dermatitis—Vincristine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Levorphanol—Nausea—Carmustine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Levorphanol—Vomiting—Mitoxantrone—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Levorphanol—Rash—Mitoxantrone—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Levorphanol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Levorphanol—Nausea—Vincristine—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Levorphanol—Nausea—Mitoxantrone—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Levorphanol—Convulsion—Methotrexate—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Levorphanol—Confusional state—Methotrexate—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Levorphanol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Levorphanol—Hypotension—Methotrexate—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Levorphanol—Insomnia—Methotrexate—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Levorphanol—Dyspepsia—Methotrexate—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Levorphanol—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Levorphanol—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Levorphanol—Urticaria—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Levorphanol—Abdominal pain—Methotrexate—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Levorphanol—Pruritus—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Levorphanol—Dizziness—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Levorphanol—Vomiting—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Levorphanol—Rash—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Levorphanol—Dermatitis—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Levorphanol—Nausea—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
